Carey Hwang

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

Cynthia L. Gay, Ronald J. Bosch, Justin Ritz et al. · The Journal of Infectious Diseases · 2017 · 221 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

Chloe Orkin, Kathleen Squires, Jean‐Michel Molina et al. · Clinical Infectious Diseases · 2018 · 168 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 145 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir

Marc Bifano, Carey Hwang, B. Oosterhuis et al. · Antiviral Therapy · 2013 · 95 citations

Medicine, Pharmacokinetics, Pharmacology +17